Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Foamix, a developer of dermatological foam medications, and Galderma have signed an agreement to jointly develop innovative medicated foam.
Subscribe to our email newsletter
Under this agreement, Foamix will develop the foam formulation of the product and Galderma will subsequently conduct all other activities (clinical, non-clinical, etc). Foamix will receive staged payments on successful completion of the technical milestones of the project.
This new treatment contains a novel drug for the therapy of certain skin diseases.